Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: wimmer k. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162. N Engl J Med. 2021. PMID: 34320285 Clinical Trial.
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M. Strobl S, et al. Among authors: wimmer k. Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Curr Treat Options Oncol. 2018. PMID: 29527635 Review.
Expert Discussion: ASCO 2022.
Balic M, Wimmer K, Suppan C, Silovski T, Brunner C. Balic M, et al. Among authors: wimmer k. Breast Care (Basel). 2022 Aug;17(4):430-436. doi: 10.1159/000525966. Epub 2022 Jul 8. Breast Care (Basel). 2022. PMID: 36156916 Free PMC article. No abstract available.
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.
Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, Exner R, Filipits M, Bago-Horvath Z, Rudas M, Bartsch R, Gnant M, Singer CF, Balic M, Egle D, Oehler R, Fitzal F. Wimmer K, et al. J Exp Clin Cancer Res. 2023 Nov 14;42(1):300. doi: 10.1186/s13046-023-02876-x. J Exp Clin Cancer Res. 2023. PMID: 37957750 Free PMC article. Clinical Trial.
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.
Marhold M, Udovica S, Halstead A, Hirdler M, Ferner M, Wimmer K, Bago-Horvath Z, Exner R, Fitzal F, Strasser-Weippl K, Robinson T, Bartsch R. Marhold M, et al. Among authors: wimmer k. Oncoimmunology. 2023 Nov 13;12(1):2275846. doi: 10.1080/2162402X.2023.2275846. eCollection 2023. Oncoimmunology. 2023. PMID: 38025838 Free PMC article.
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F. Wimmer K, et al. Breast Cancer Res Treat. 2024 Jun;205(2):227-239. doi: 10.1007/s10549-023-07186-6. Epub 2024 Jan 25. Breast Cancer Res Treat. 2024. PMID: 38273214 Free PMC article.
196 results